GlaxoSmithKline Net Income 2010-2022 | GSK

GlaxoSmithKline annual/quarterly net income history and growth rate from 2010 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • GlaxoSmithKline net income for the quarter ending March 31, 2022 was $2.418B, a 63.41% increase year-over-year.
  • GlaxoSmithKline net income for the twelve months ending March 31, 2022 was $6.968B, a 1.63% increase year-over-year.
  • GlaxoSmithKline annual net income for 2021 was $6.03B, a 18.31% decline from 2020.
  • GlaxoSmithKline annual net income for 2020 was $7.382B, a 24.46% increase from 2019.
  • GlaxoSmithKline annual net income for 2019 was $5.931B, a 22.65% increase from 2018.
GlaxoSmithKline Annual Net Income
(Millions of US $)
2021 $6,030
2020 $7,382
2019 $5,931
2018 $4,836
2017 $1,974
2016 $1,236
2015 $12,877
2014 $4,666
2013 $8,807
2012 $7,520
2011 $8,757
2010 $2,865
2009 $8,877
GlaxoSmithKline Quarterly Net Income
(Millions of US $)
2022-03-31 $2,418
2021-12-31 $990
2021-09-30 $1,611
2021-06-30 $1,950
2021-03-31 $1,480
2020-12-31 $962
2020-09-30 $1,607
2020-06-30 $2,808
2020-03-31 $2,005
2019-12-31 $1,697
2019-09-30 $1,914
2019-06-30 $1,239
2019-03-31 $1,081
2018-12-31 $1,325
2018-09-30 $1,848
2018-06-30 $600
2018-03-31 $1,063
2017-12-31 $-678
2017-09-30 $1,587
2017-06-30 $-230
2017-03-31 $1,296
2016-12-31 $319
2016-09-30 $1,061
2016-06-30 $-624
2016-03-31 $404
2015-12-31 $-541
2015-09-30 $834
2015-06-30 $228
2015-03-31 $12,248
2014-12-31 $1,556
2014-09-30 $648
2014-06-30 $1,114
2014-03-31 $1,123
2013-12-31 $3,924
2013-09-30 $1,566
2013-06-30 $1,605
2013-03-31 $1,466
2012-12-31 $1,370
2012-09-30 $1,807
2012-06-30 $1,981
2012-03-31 $2,139
2011-12-31 $1,972
2011-09-30 $2,191
2011-06-30 $1,802
2011-03-31 $2,442
2010-12-31 $-1,116
2010-09-30 $2,082
2010-06-30 $-427
2010-03-31 $2,056
2009-12-31 $2,724
2009-09-30 $2,251
2009-06-30 $2,262
2009-03-31 $1,681
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $113.161B $46.910B
Glaxo has 3 core businesses - Pharmaceuticals, Vaccines and Consumer Healthcare. The company has made significant progress in expanding its presence in emerging markets by acquiring product portfolios from companies like Bristol-Myers and UCB. In August 2019, Glaxo and Pfizer merged their consumer healthcare unit into a new JV. Glaxo owns a controlling stake in the JV. Glaxo plans to split itself into two standalone companies. The new Glaxo will be a biopharma company. Glaxo intends to separate its Consumer Healthcare segment into a standalone company in 2022. The independent Consumer Healthcare company will be named Haleon. In 2015, Glaxo divested two quadrivalent meningitis ACWY vaccines ' Nimenrix and Mencevax ' to Pfizer, a portfolio of OTC brands to Perrigo, and all its remaining rights to Arzerra for auto-immune indications including multiple sclerosis to Novartis. In January 2019, Glaxo acquired Tesaro, an oncology focused biotech company, which added the PARP inhibitor Zejula to its portfolio.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $465.705B 17.91
Pfizer (PFE) United States $294.404B 10.27
Eli Lilly (LLY) United States $283.955B 33.50
AbbVie (ABBV) United States $266.851B 11.70
Merck (MRK) United States $236.570B 13.36
Novartis AG (NVS) Switzerland $200.009B 14.40
Novo Nordisk (NVO) Denmark $0.000B 32.07